Vebreltinib natara nkwenye ọnọdụ na China maka MET-Amplified NSCLC

Na June 30, ọgwụ mgbochi MET nke Avistone mepụtara n'onwe ya, Vebreltinib, natara nkwenye ọnọdụ site n'aka National Medical Products Administration (NMPA) nke China maka ọgwụgwọ ndị ọrịa nwere kansa akpa ume nke na-abụghị obere mkpụrụ ndụ (NSCLC) nke nwere mmụba MET. Nke a bụ ihe ngosi nke atọ akwadoro maka Vebreltinib na China na ọgwụgwọ mbụ nke otu ọgwụ akwadoro kpọmkwem maka ndị ọrịa NSCLC nke MET na-amụbawanye.

Nkwenye nke Vebreltinib na China maka ihe ngosi ọhụrụ a - ịgwọ ndị ọrịa nwere kansa akpa ume nke na-abụghị obere mkpụrụ ndụ (NSCLC) nke nwere mmụba MET - dabere na nsonaazụ dị mma sitere na Cohort 2 na Cohort 3 nke ọmụmụ KUNPENG (NCT04258033).

Ndị otu Cohort nke abụọ tinyere ndị ọrịa a gwọrọ n'oge gara aga nwere NSCLC amplified MET bụ ndị dara ọgwụgwọ nkịtị (gụnyere chemotherapy dabere na platinum), ebe ndị otu Cohort nke atọ gụnyere ndị ọrịa na-enweghị ọgwụgwọ na-enweghị ọgwụgwọ nwere NSCLC amplified MET bụ ndị jụrụ chemotherapy.

E debara aha ndị ọrịa 86 nwere NSCLC dị elu n'ógbè ma ọ bụ nke nwere ọrịa kansa n'ofe otu abụọ ahụ (33 na Cohort 2 na 53 na Cohort 3). Nsonaazụ ọmụmụ ahụ gosiri ọnụego nzaghachi ebumnuche (ORR) nke 48.8%, ọnụego njikwa ọrịa (DCR) nke 77.9%, oge nzaghachi etiti (DoR) nke ọnwa 12.1, ndụ na-enweghị ọganihu (PFS) nke ọnwa 7.4, na ndụ zuru oke (OS) nke ọnwa 13.9.

N'ime ndị otu Cohort 2 (ndị ọrịa 33 a gwọrọla n'oge gara aga), ORR bụ 48.5%, DCR bụ 78.8%, DoR nke etiti bụ ọnwa 11.0, PFS nke etiti bụ ọnwa 6.2, na OS nke etiti bụ ọnwa 11.7.

N'ime ndị otu Cohort 3 (ndị ọrịa 53 na-enweghị ahụmịhe ọgwụgwọ), ORR bụ 49.1%, DCR bụ 77.4%, DoR etiti bụ ọnwa 12.1, PFS etiti bụ ọnwa 8.3, na OS etiti bụ ọnwa 15.5.

N'ọmụmụ ihe KUNPENG, Kọmitii Nyocha Onwe Onye (IRC) nyochachara ndị ọrịa 21 nwere nsogbu ụbụrụ mbụ. N'ime ndị a, mmadụ 10 nwetara nzaghachi akụkụ (PR) akwadoro, nke butere ORR nke 47.6%, DCR nke 85.7%, na DoR etiti nke ọnwa 11.0. Na mgbakwunye, PFS na OS etiti bụ ọnwa 8.3 na ọnwa 14.7, n'otu n'otu.

Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.

Nọmba ekwentị: 4008803716

Email：myimmnet@163.com